These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9797804)

  • 1. [Cancer-associated gene abnormalities and chemosensitivity].
    Sakamoto M; Umayahara K; Sakamoto H; Kawasaki K; Suehiro Y; Kunugi T; Akiya T; Iwabuchi H; Sakunaga H; Muroya T; Kikuchi Y; Sugishita T; Tenjin Y; Gray JW; Tanaka T
    Gan To Kagaku Ryoho; 1998 Oct; 25(12):1819-31. PubMed ID: 9797804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
    Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Establishment of 5 resistant ovarian cancer cell strains and expression of resistance-related genes].
    Luan YZ; Li L; Li DR; Zhang W; Tang BJ
    Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):403-7. PubMed ID: 15312326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
    Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
    Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
    Chang FL; Ling YF; Lai MD
    Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
    Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
    Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated p53 and p21waf1 mRNA expression in blood lymphocytes from lung cancer patients with chemoresistance.
    Shih CM; Chen K; Wang YC; Lee PJ; Wang YC
    Cancer Detect Prev; 2007; 31(5):366-70. PubMed ID: 18035504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
    L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
    Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
    Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F
    Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of wild-type p53 gene on the chemotherapy sensitivity of ovarian cancer SKOV-3 cells to cisplatin].
    Jin Z; Guan T; Li S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Jun; 19(3):218-20. PubMed ID: 12048682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes].
    Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH
    Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer.
    Takano M; Kudo K; Goto T; Yamamoto K; Kita T; Kikuchi Y
    Hum Cell; 2001 Dec; 14(4):267-71. PubMed ID: 11925927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
    Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
    Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
    Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
    Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
    Qian XL; Peng ZL; Liu SL
    Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.